Effects of Botulinum Toxin Type A on the Nociceptive and Lemniscal Somatosensory Systems in Chronic Migraine: An Electrophysiological Study.
botulinum toxin type A
central sensitization
lemniscal system
migraine
pain
peripheral sensitization
trigemino-cervical complex
Journal
Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765
Informations de publication
Date de publication:
14 01 2023
14 01 2023
Historique:
received:
24
12
2022
revised:
08
01
2023
accepted:
12
01
2023
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
(1) Background: OnabotulinumtoxinA (BoNT-A) is a commonly used prophylactic treatment for chronic migraine (CM). Although randomized placebo studies have shown its clinical efficacy, the mechanisms by which it exerts its therapeutic effect are still incompletely understood and debated. (2) Methods: We studied in 15 CM patients the cephalic and extracephalic nociceptive and lemniscal sensory systems using electrophysiological techniques before and 1 and 3 months after one session of pericranial BoNT-A injections according to the PREEMPT protocol. We recorded the nociceptive blink reflex (nBR), the trigemino-cervical reflex (nTCR), the pain-related cortical evoked potential (PREP), and the upper limb somatosensory evoked potential (SSEP). (3) Results: Three months after a single session of prophylactic therapy with BoNT-A in CM patients, we found (a) an increase in the homolateral and contralateral nBR AUC, (b) an enhancement of the contralateral nBR AUC habituation slope and the nTCR habituation slope, (c) a decrease in PREP N-P 1st and 2nd amplitude block, and (d) no effect on SSEPs. (4) Conclusions: Our study provides electrophysiological evidence for the ability of a single session of BoNT-A injections to exert a neuromodulatory effect at the level of trigeminal system through a reduction in input from meningeal and other trigeminovascular nociceptors. Moreover, by reducing activity in cortical pain processing areas, BoNT-A restores normal functioning of the descending pain modulation systems.
Identifiants
pubmed: 36668895
pii: toxins15010076
doi: 10.3390/toxins15010076
pmc: PMC9863777
pii:
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
J Biol Chem. 1992 Oct 25;267(30):21338-43
pubmed: 1356988
Headache. 2020 Jul;60(7):1259-1272
pubmed: 32602955
Neurotoxicology. 2005 Oct;26(5):785-93
pubmed: 16002144
PLoS One. 2014 Jun 17;9(6):e100198
pubmed: 24936654
Headache. 2004 Jan;44(1):35-42; discussion 42-3
pubmed: 14979881
Pain. 2003 Nov;106(1-2):81-9
pubmed: 14581114
Neuroscience. 2017 Jun 3;352:155-169
pubmed: 28389376
Toxins (Basel). 2016 May 25;8(6):
pubmed: 27231940
Neurology. 2004 Mar 9;62(5):788-90
pubmed: 15007133
Neurol Sci. 2003 May;24 Suppl 2:S97-100
pubmed: 12811603
Headache. 1998 Jul-Aug;38(7):497-506
pubmed: 15613165
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Pain. 2009 Jul;144(1-2):156-61
pubmed: 19457613
Cephalalgia. 2010 Jul;30(7):804-14
pubmed: 20647171
Trends Pharmacol Sci. 2005 Feb;26(2):62-8
pubmed: 15681022
J Neural Transm (Vienna). 2014 Jun;121(6):665-9
pubmed: 24420081
Brain. 2022 Jul 29;145(7):2436-2449
pubmed: 34932787
Cephalalgia. 2011 Feb;31(3):301-15
pubmed: 20813784
J Comp Neurol. 2009 Jul 20;515(3):331-48
pubmed: 19425099
Nat Rev Neurol. 2016 Aug;12(8):455-64
pubmed: 27389092
Philos Trans R Soc Lond B Biol Sci. 1999 Feb 28;354(1381):259-68
pubmed: 10212474
J Headache Pain. 2016;17:35
pubmed: 27084694
Cephalalgia. 2010 Feb;30(2):207-13
pubmed: 19489879
Cephalalgia. 2007 Jul;27(7):803-8
pubmed: 17598762
Biochem Pharmacol. 2000 Jun 1;59(11):1403-6
pubmed: 10751549
J Neurosci. 2019 Mar 6;39(10):1867-1880
pubmed: 30622169
J Headache Pain. 2015;16:555
pubmed: 26245187
Eur Neurol. 2019;81(1-2):37-46
pubmed: 31013496
Headache. 2009 Apr;49(4):498-508
pubmed: 19245386
J Urol. 2005 Sep;174(3):977-82; discussion 982-3
pubmed: 16094018
Toxins (Basel). 2019 Aug 05;11(8):
pubmed: 31387301
Neurochem Int. 2012 Jul;61(2):236-9
pubmed: 22580329
Clin Neurophysiol. 2000 Mar;111(3):413-6
pubmed: 10699400
Pain Res Manag. 2014 May-Jun;19(3):126-32
pubmed: 24851237
Membranes (Basel). 2014 Aug 19;4(3):525-64
pubmed: 25257900
Biochem J. 2012 Jan 1;441(1):443-52
pubmed: 21929507
Neuroscience. 2011 Jul 14;186:201-7
pubmed: 21539899
Clin Neurophysiol. 2007 Feb;118(2):457-63
pubmed: 17141567
Headache. 2011 Oct;51(9):1358-73
pubmed: 21883197
Cephalalgia. 2006 Sep;26(9):1106-14
pubmed: 16919061
Toxins (Basel). 2022 Sep 05;14(9):
pubmed: 36136557
Clin Neurophysiol. 2011 Dec;122(12):2482-7
pubmed: 21641860
Toxins (Basel). 2019 Jan 06;11(1):
pubmed: 30621330
Neuropharmacology. 2013 Jul;70:331-7
pubmed: 23499661
Clin Neurophysiol. 2010 Sep;121(9):1563-1568
pubmed: 20392666
Pain. 2015 May;156(5):820-824
pubmed: 25735000
Cephalalgia. 2022 Oct;42(11-12):1236-1245
pubmed: 35637558
Cephalalgia. 2014 Oct;34(11):853-69
pubmed: 24694964
BMC Neurol. 2010 Dec 30;10:126
pubmed: 21192822
Neurophysiol Clin. 1999 Feb;29(1):7-38
pubmed: 10093816
Clin Neurophysiol. 2012 Jan;123(1):13-20
pubmed: 22030138
Brain. 2007 Mar;130(Pt 3):765-70
pubmed: 17251239
Headache. 2012 Nov-Dec;52(10):1456-70
pubmed: 22830411
Pain. 2004 Jan;107(1-2):125-33
pubmed: 14715398
Toxins (Basel). 2020 Dec 17;12(12):
pubmed: 33348571
Prog Neurobiol. 2014 Aug-Sep;119-120:39-59
pubmed: 24915026
J Headache Pain. 2015;16:532
pubmed: 26018292
Toxins (Basel). 2019 Feb 19;11(2):
pubmed: 30791373
Toxicon. 2000 Feb;38(2):245-58
pubmed: 10665805
News Physiol Sci. 2000 Apr;15:94-97
pubmed: 11390886
Neurobiol Dis. 2012 Dec;48(3):367-78
pubmed: 22820141
Nat Clin Pract Neurol. 2008 Dec;4(12):676-85
pubmed: 19043424
Eur J Neurol. 2012 May;19(5):703-11
pubmed: 22136117
Pain. 2004 Mar;108(1-2):124-8
pubmed: 15109515